oppn parties Maiden Pharma Cough Syrup Case: Did WHO Act In Haste?

News Snippets

  • Delhi chief minister Arvind Kejriwal, referring to a spate of FIRs for putting up posters in Delhi which said "Modi Hatao, Desh Bachao", said that even the British did not act in such manner
  • The 2023-24 Appropriation BIll, which allows the government to spend Rs 45 lakh crore in the fiscal, was passed by Lok Sabha in 9 minutes without any discussion
  • Sources say that Amritpal Singh fled to Haryana and may now be in Uttarakhand
  • Experts say that Rahul Gandhi's disqualification from Parliament will kick in immediately as the conviction has not been stayed
  • Tatas to invest $2bn in super app Tata Neu
  • Chief Economic Advisor V Anantha Nageswaran has said that inflation will drop as commodity and food prices have fallen
  • Government will define quality norms to ensure better 5G service
  • Stocks tumble again on Thursday after two sessions of recovery: Sensex loses 289 points to 57925 and Nifty goes down by 75 points to 17076
  • Amicus curiae and senior advocate K V Vishwanathan has told the Supreme Court that the changes made in law and three extensions given to the present director of Enforcement Directorate are illegal and will imperil the integrity of the agency
  • Supreme Court says it cannot judicially direct the government to acquire land or buildings near the court for advocates' chambers
  • ISSF Cup shooting: Indian pair of Rhythm Sangwan and Varun Tomar win silver in 10m sir rifle mixed team event
  • WPL: UP Warriorz take on Mumbai Indians in the Eliminator today. The winner will play Delhi Capitals in the finals
  • World Boxing: Four Indians - Nikhat Zareen, Nitu Ghanghas, Lovelina Borgohain and Saweety Boora - enter the frinals in their respective category
  • Bombay HC imposes costs and dismisses a petition by a housing society that sought to have a community-wise cap on residents
  • Delhi Police files 159 FIRs for defacement of public property and 49 for posters saying 'Modi Hatao Desh Bachao'
Rahul Gandhi disqualified from Parliament, Wayanad Lok Sabha seat declared vacant
oppn parties
Maiden Pharma Cough Syrup Case: Did WHO Act In Haste?

By Sunil Garodia
First publised on 2022-12-16 06:50:54

About the Author

Sunil Garodia Editor-in-Chief of indiacommentary.com. Current Affairs analyst and political commentator.

A few months ago, the World Health Organization (WHO) had insinuated that India's Maiden Pharmaceuticals, the Haryana-based drug manufacturer, had supplied sub-standard paediatric cough syrups to Gambia and linked it to the death of 66 children in that country. Now, after the results of the tests conducted on the samples of final products and raw materials drawn from the manufacturing facilities of the drug firm have confirmed that there was nothing wrong with the syrups and they met with all prescribed standards, the government of India has slammed the WHO for drawing hasty conclusions and unfairly linking the death of the children to the alleged infirmities in the cough syrups without conducting a thorough test. Surprisingly, as the government has stated, WHO has, till now, refused to share any details as to how it arrived at the conclusion that linked the deaths to the cough syrups despite several reminders.

The hasty action of WHO is not acceptable, more so as it has failed to produce material to support the claims. India has earned the reputation of supplying excellent quality pharmaceuticals products all over the world. Its companies follow good manufacturing practices and are being regularly inspected by local authorities and even international authorities. If baseless charges, not backed by supporting material, are made against one Indian company it will damage the reputation of the entire industry.

India must take up the matter with WHO at the highest level. It should submit the findings of the tests conducted and demand the same from WHO. If WHO is unable to substantiate its claims then it should issue an unconditional apology and clear the drug manufacturer. Further, there must a defined process at WHO through which such alerts are issued. It must do so only after conducting acceptable preliminary tests and provide the results to the government of the originating country. In case of Maiden Pharmaceuticals it seems that WHO is trying to hide its inefficiency as it has failed to provide supporting material even though nearly three months have passed since it first sounded the alert. This is damaging for the whole pharmaceuticals ecosystem.